Related Blog Posts
Eli Lilly Isnt Planning to Buy Its Way Around the Patent Cliff - Health Blog - WSJ
37 minutes ago ago from Health Blog - WSJ
By Jacob Goldstein Eli Lilly knows a thing or two about the patent cliff: Between now and 2013, patent protection will expire on drugs that account for more than half of its current revenue, this morning's WSJ notes . Plenty of big pharma players face this kind of problem, and many companies have looked to buy their way out of trouble witness this year's big Pfizer-Wyeth and Merck-Schering Plough deals. But Lilly emphasized at its ...
Related contentWhy The Limp Sales?
21 hours ago ago from EGMN: Notes from the Road
After years of go-go growth, it appears that the market for erectile dysfunction drugs in the U.S. and overseas is flat. Courtesy Flickr user fhwrdh That's according to Eli Lilly, which told investors this morning that the global market for ED drugs grew just 1% over the first 9 months of this year. Will this market shrinkage cause primary care doctors to find themselves in the crosshairs of promotion? Lilly crowed that ...
Related contentLilly Stock Going Down
12 hours ago ago from Mental Health Blogs
For those of you interested in the stock markets, one of the big stories out there today was that Lilly's stock dropped about 3 percent today a sizable move for a fairly stable stock. Reportedly, Lilly CEO John Lechleiter gave a speech before analysts in New York and offered little hope for how the company will fare financially in 2011 and beyond as Zyprexa and, then, Cymbalta come off-patent. What no one has picked up on in the ...
Related contentRelated News
Eli Lilly predicts earnings growth, touts pipeline
20 hours ago ago from PopEater
INDIANAPOLIS -Eli Lilly & Co. said Thursday earnings per share could grow more than 10 percent next year, but the drugmaker's stock dropped as its 2009 forecast fell short of Wall Street expectations. Indianapolis-based Lilly also touted its pipeline of drugs under development during a Webcast of its annual meeting with investors in New York. Company leaders said they expect to launch two new medicines per year starting in 2013. But analysts ...
Related content
